LJAC
KYMR icon

L.J. Altfest & Co’s Kymera Therapeutics KYMR Stock Holding History

L.J. Altfest & Co’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,318
Closed -$301K – 358
2025
Q3 		$301K Buy
+5,318
New +$240K 0.03% 286

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

L.J. Altfest & Co's KYMR Position: Q4 2025 in Review

L.J. Altfest & Co sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 5,318 shares — an estimated $301K sold.

L.J. Altfest & Co first reported a position in KYMR in Q3 2025 and held it in 1 quarter. The position peaked at $301K in Q3 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • L.J. Altfest & Co reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • L.J. Altfest & Co sold 5,318 Kymera Therapeutics shares in Q4 2025, an estimated $301K.
  • L.J. Altfest & Co first reported a position in Kymera Therapeutics in Q3 2025 and held it in 1 quarter.
  • L.J. Altfest & Co's Kymera Therapeutics position peaked at $301K in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on L.J. Altfest & Co's 13F filing for Q4 2025, filed 23 Jan 2026.